Cochrane · systematic review · CD013125
Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta‐analysis
Komolafe, O, Roberts, D, Freeman, SC, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
23
current version
GRADE rated
21
No studies
2
Included studies
NR
No studies 2 · 8.7%Ungraded 0 · 0%Very low 18 · 78.3%Low 3 · 13%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis
Population: people with liver cirrhosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Interventions | no estimate extracted | NR | No studies |
No active intervention | no estimate extracted | NR | No studies |
Rifaximin (3 RCTs, 479 participants) | HR 0.57 [0.33, 1] | NR | Very low Downgraded: risk of bias, imprecision |
Norfloxacin (4 RCTs, 546 participants) | HR 0.74 [0.49, 1.09] | NR | Very low Downgraded: risk of bias, imprecision |
Ciprofloxacin (3 RCTs, 255 participants) | HR 0.61 [0.31, 1.16] | NR | Very low Downgraded: risk of bias, imprecision |
Sulfamethoxazole +trimethoprim (1 RCT, 60 participants) | HR 0.47 [0.2, 1] | NR | Very low Downgraded: risk of bias, imprecision |
Norfloxacin +rifaximin (no direct RCT) | HR 0.4 [0.12, 1.17] | NR | Very low Downgraded: risk of bias, imprecision |
Rufloxacin (no direct RCT) | HR 1.45 [0.27, 8.21] | NR | Very low Downgraded: risk of bias, imprecision |
Rifaximin (2 RCTs, 353 participants) | Rate ratio 1.66 [0.98, 2.9] | NR | Very low Downgraded: risk of bias, imprecision |
Rifaximin (1 RCT, 299 participants) | OR 1.01 [0, 853.21] | NR | Very low Downgraded: risk of bias, imprecision |
Norfloxacin (no direct RCT) | OR 11.85 | NR | Very low Downgraded: risk of bias, imprecision |
Rifaximin (3 RCTs, 418 participants) | Rate ratio 1.15 [0.98, 1.34] | NR | Very low Downgraded: risk of bias, imprecision |
Ciprofloxacin (3 RCT; 255 participants) | Rate ratio 0.72 [0.49, 1.05] | NR | Very low Downgraded: risk of bias, imprecision |
Sulfamethoxazole + trimethoprim (1 RCT, 60 participants) | Rate ratio 0.19 [0.02, 0.81] | NR | Low Downgraded: risk of bias, imprecision |
Norfloxacin (1 RCT, 68 participants) | HR 0.93 [0.31, 3.44] | NR | Very low Downgraded: risk of bias, imprecision |
Ciprofloxacin (no direct RCT) | HR 0.62 [0.12, 3.31] | NR | Very low Downgraded: risk of bias, imprecision |
Sulfamethoxazole + trimethoprim (no direct RCT) | HR 2.62 [0.62, 11.91] | NR | Very low Downgraded: risk of bias, imprecision |
Rifaximin (2 RCTs, 106 participants) | HR 7.8 [0.13, 4647.11] | NR | Very low Downgraded: risk of bias, imprecision |
Norfloxacin (3 RCTs, 255 participants) | HR 0.16 [0, 1.56] | NR | Very low Downgraded: risk of bias, imprecision |
Norfloxacin + neomycin (1 RCT, 22 participants) | Rate ratio 0.06 [0, 0.33] | NR | Low Downgraded: risk of bias, imprecision |
Norfloxacin + rifaximin (no direct RCT) | Rate ratio 0.33 [0.04, 1.4] | NR | Very low Downgraded: risk of bias, imprecision |
Rifaximin (3 RCTs, 575 participants) | Rate ratio 0.61 [0.46, 0.8] | NR | Low Downgraded: risk of bias, imprecision |
Norfloxacin (3 RCTs, 439 participants) | Rate ratio 0.81 [0.58, 1.12] | NR | Very low Downgraded: risk of bias, imprecision |